App-Quantinova.ai

Development and validation of blood tumor mutational burden reference standards

Eun-Ang Rabier-Moreau - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

James Spicer - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Pembrolizumab

Precision microbiome mapping identifies a microbiome signature predictive of Immune checkpoint inhibitor response across multiple research study cohorts

Matthew Robinson - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)

Sophie Wildsmith - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Ticilimumab

An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

Mark Middleton - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Skin carcinoma

Nivolumab

The mesenchymal stromal compartment in colorectal cancer greatly alters the innate tumour immune microenvironment both in 2D and 3D culture systems

Niamh Leonard - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A

Aurelien Marabelle - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

Johanna Bendell - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Pembrolizumab

A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model

David Ciccone - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on the IL23/IFNg axis

Lo, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Anti-CTLA4

Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease

Rodger, B - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

N/A

Integrin-b7+ cytotoxic MAIT cells are expanded in the colon of Ulcerative Colitis patients, correlate with disease severity and are targeted by vedolizumab therapy.

Hermangild Kottoor - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Entyvio

New insights into the pathogenic potential and signalling network of NKG2D+ CD4+ T-cells in Crohn’s Disease

Modos, D - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Interferon Gamma

A review of the newly implemented Inflammatory Bowel Disease dietetic service

Norman, E - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Inflammatory bowel disease does not preclude the presence of environmental enteropathy in Zambian adults

Hodges, P - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

An examination of resting state functional connectivity in patients with active Crohn’s disease

Thapaliya, G - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

The role of α4β7+CLA+ ‘dual tropic’ T cells in inflammatory bowel disease

Gordon, H - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

TIGIT expression differentiates regulatory from inflammatory Th1* gut-homing effector CD4+ T cells in inflammatory bowel disease patients

Heredia, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Unravelling the microbial-derived metabolic alterations in a T-bet-/- x RAG2-/- mouse colitis model

Liu, Z - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Anorectal Cream

Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course

Heredia, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Filters

45280 Abstracts